Projection resolved optical coherence tomography angiography to distinguish flow signal in retinal angiomatous proliferation from flow artifact.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 25 01 2019
accepted: 03 05 2019
entrez: 16 5 2019
pubmed: 16 5 2019
medline: 30 1 2020
Statut: epublish

Résumé

To investigate whether hyperreflective foci (HRF) exhibit flow projection artifact on OCTA, and study the efficacy of commercial projection artifact removal software (PAR-OCTA, Optovue, Inc), and a custom projection resolved OCTA (PR-OCTA) in distinguishing artifacts from true flow in retinal angiomatous proliferation (RAP). The study included five eyes with HRF representing pigment migration in dry age-related macular degeneration (AMD), five eyes with leaking treatment-naïve RAP, and ten eyes with diabetic hard exudates. We examined flow signal on OCTA cross-sections using PAR, and performed PR-OCTA to study the effect of increasingly stringent projection removal thresholds. Flow signal intensity was analyzed and quantified using imageJ (NIH, Bethesda, MD, USA), by calculating the percentage of red pixels (R) representing flow, compared to green (G) and blue (B) pixels. PAR-OCTA cross sections revealed persistent flow signal in all HRF, including RAP, hard exudates and pigment migration. In RAP, PR-OCTA detected intransigent flow, irrespective of the flow removal threshold. Mean R in the five RAP lesions remained higher than mean G and B at the most stringent PR-OCTA threshold (40.96% vs 29.52 and 29.52%, respectively), denoting persistence of flow. In contrast, increasing the PR-OCTA threshold in pigment migration and hard exudates removed the flow signal, with a statistically significant decrease in mean R with increasing threshold. (p = 0.017 and 0.0029, respectively). Commercial PAR-OCTA is not completely effective at removing artifactual flow in hard exudates and HRF related to pigment migration. Custom built PR-OCTA, using a sliding scale of threshold, allowed us to distinguish true flow in RAP from artifactual flow in avascular HRF. Further studies are needed to validate the optimum threshold for projection artifact removal, which would preserve true flow in RAP and the small intraretinal capillaries.

Identifiants

pubmed: 31091288
doi: 10.1371/journal.pone.0217109
pii: PONE-D-19-02475
pmc: PMC6519823
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0217109

Subventions

Organisme : NIDDK NIH HHS
ID : DP3 DK108248
Pays : United States

Déclaration de conflit d'intérêts

The authors have received research instrument support from Optovue, Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Retina. 2017 Feb;37(2):234-246
pubmed: 27749497
Am J Ophthalmol. 2016 Apr;164:89-98
pubmed: 26868959
Opt Express. 2012 Feb 13;20(4):4710-25
pubmed: 22418228
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5548-5555
pubmed: 29075766
Am J Ophthalmol Case Rep. 2017 Oct 06;8:53-57
pubmed: 29260118
Biomed Opt Express. 2017 Feb 15;8(3):1536-1548
pubmed: 28663848
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT27-36
pubmed: 27409483
Sci Rep. 2017 Jun 9;7(1):3150
pubmed: 28600515
Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5780-5787
pubmed: 27792812
Biomed Opt Express. 2016 Feb 09;7(3):816-28
pubmed: 27231591
Graefes Arch Clin Exp Ophthalmol. 1992;230(1):11-9
pubmed: 1547961
Can J Ophthalmol. 2017 Aug;52(4):419-424
pubmed: 28774527
Retina. 2017 Oct;37(10):1873-1879
pubmed: 28079756
Ophthalmology. 2013 May;120(5):1038-45
pubmed: 23352193
Am J Ophthalmol. 2012 Apr;153(4):710-7, 717.e1
pubmed: 22137207
Graefes Arch Clin Exp Ophthalmol. 2007 Feb;245(2):295-300
pubmed: 16738855
JAMA Ophthalmol. 2016 Dec 1;134(12):1411-1419
pubmed: 27812696
Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2913-2922
pubmed: 30025133
Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):1944-1952
pubmed: 29677356
Sci Rep. 2017 Feb 10;7:42201
pubmed: 28186181
Br J Ophthalmol. 2010 Jun;94(6):701-5
pubmed: 19854733
Ophthalmology. 2009 May;116(5):914-20
pubmed: 19410950
Retina. 2016 Dec;36 Suppl 1:S40-S49
pubmed: 28005662
Retina. 2012 Jan;32(1):77-85
pubmed: 21866075
Retina. 2015 Apr;35(4):603-13
pubmed: 25621948
Retina. 2018 Jul;38(7):1289-1300
pubmed: 29059100
Ophthalmology. 2011 Apr;118(4):687-93
pubmed: 21093923
Ophthalmol Retina. 2018 Nov;2(11):1097-1106
pubmed: 31047548
Retina. 2012 Feb;32 Suppl 1:416-34
pubmed: 22451953

Auteurs

Alaa E Fayed (AE)

Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Department of Ophthalmology, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.

Amani A Fawzi (AA)

Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH